Biaryl anthranilides are reported as potent and selective full agonists for the high affinity niacin receptor GPR109A. The SAR presented outlines approaches to reduce serum shift and both CYPCYP2C8 and CYP2C9 liabilities, while improving PK and maintaining excellent receptor activity. Compound 2i exhibited good in vivo antilipolytic efficacy while providing a significantly improved therapeutic index over vasodilation (flushing) with respect to niacin in the mouse model.

Download full-text PDF

Source
http://dx.doi.org/10.1021/jm700942dDOI Listing

Publication Analysis

Top Keywords

biaryl anthranilides
8
full agonists
8
agonists high
8
high affinity
8
affinity niacin
8
niacin receptor
8
discovery biaryl
4
anthranilides full
4
receptor biaryl
4
anthranilides reported
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!